Bruce Rashbaum
Internal Medicine · Washington, DCNPI 1568555456
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $61,450 of the $85,718 with a category attached, or 71.7%. Gilead accounts for 78.2% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $81,160 and has fallen 99.9% since, to $63 in 2021. Among internal medicine clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 242 payments — averaging $354.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$67K
- Janssen Products, LP$16K
- Johnson & Johnson$800
- Medicure Pharma Inc.$300
- Theratechnologies Inc.$272
- Merck$189
- plus $1K from 19 others
Across 26 payments — averaging $6892.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$169K
- Janssen Research & Development, LLC$10K
What the payments were for
- Consulting fees$4,5105%
- Speaking & faculty fees$61,45072%
- Travel & lodging$14,89017%
- Food & beverage$4,8646%
- Education$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 105 | $67,043 |
| Janssen Products, LP | 20 | $15,972 |
| Johnson & Johnson | 32 | $800 |
| Medicure Pharma Inc. | 1 | $300 |
| Theratechnologies Inc. | 12 | $272 |
| Merck | 14 | $189 |
| Amgen | 5 | $182 |
| Kowa Pharmaceuticals America, Inc. | 10 | $178 |
| Novo Nordisk | 5 | $97 |
| Viiv Healthcare Company | 4 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $87 |
| AbbVie(2 entities) | 4 | $68 |
| Napo Pharmaceuticals Inc | 4 | $66 |
| Endo Pharmaceuticals Inc. | 3 | $57 |
| Mylan Institutional Inc. | 3 | $56 |
| Adlon Therapeutics L.p. | 3 | $51 |
| Arbor Pharmaceuticals, Inc. | 3 | $42 |
| Lilly USA, LLC | 2 | $34 |
| AstraZeneca | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Mylan Pharmaceuticals Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Pfizer | 1 | $16 |
| Aytu Biopharma, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biktarvy$26,579
- Symtuza$15,583
- HMG-CoA reductase inhibitor.$300
- Repatha$122
How this compares
$85,718 in reported general payments places this provider in the 95th percentile of 645 internal medicine providers in District of Columbia.
See all internal medicine providers in District of Columbia →
Other internal medicine in Washington
- Andrea SingerWashington$850K
- Kathryn SowerwineWashington$831K
- Douglas WardWashington$233K
- Geoffrey GibneyWashington$185K
- Kevin GriffithsWashington$180K
- Jessica Wang-MemoliWashington$56K
- Dana McGintyWashington$47K
- Geeta NayyarWashington$46K
- Marie BorumWashington$42K
- Ali KhanWashington$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.